PI3-kinase mutation linked to insulin and growth factor resistance in vivo by Winnay, Jonathon N. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2016-04-01 
PI3-kinase mutation linked to insulin and growth factor resistance 
in vivo 
Jonathon N. Winnay 
Harvard Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Cellular and Molecular Physiology Commons, and the Endocrinology Commons 
Repository Citation 
Winnay JN, Solheim MH, Dirice E, Sakaguchi M, Noh HL, Kang HJ, Takahashi H, Chudasama KK, Kim JK, 
Molven A, Kahn CR, Njolstad PR. (2016). PI3-kinase mutation linked to insulin and growth factor 
resistance in vivo. University of Massachusetts Medical School Faculty Publications. https://doi.org/
10.1172/JCI84005. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/1064 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 4 0 1jci.org   Volume 126   Number 4   April 2016
Introduction
Insulin and most growth factors regulate diverse biological pro-
cesses, including cell growth, cell survival, and metabolism, by vir-
tue of their ability to activate phosphatidylinositol 3-kinase (PI3K). 
This leads to generation of phosphatidylinositol 3,4,5 trisphosphate 
(PIP3), which in turn activates AKT and other downstream kinases 
(1). Class 1a PI3Ks exist as obligate heterodimers composed of a 
regulatory subunit and a catalytic subunit. The regulatory subun-
its are products of one of 3 genes: PI3K (PIK3R1), which gives rise 
to p85α and its spliced isoforms p55α and p50α; PIK3R2, which 
encodes p85β; and PIK3R3, which encodes p55γ. The catalytic sub-
units are also encoded by 3 genes, PIK3C1, PIK3C2, and PIK3C3, 
which encode p110α, p110β, and p100γ, respectively. In most 
somatic tissues, the predominant regulatory and catalytic subunits 
are p85α and p110α. The fundamental importance of this pathway 
in insulin action, growth, and metabolism has been demonstrated 
in studies using pharmacological inhibitors of the enzyme and 
through the generation of animal models in which genes encoding 
regulatory or catalytic subunits have been disrupted (2–5). Indeed, 
homozygous deletion of the genes encoding p110α or p110β or all 
p85α gene products leads to embryonic or perinatal lethality. Con-
versely, constitutive activation of this pathway has been linked to 
the pathogenesis of a variety of cancers and diseases of overgrowth 
such as Cowden syndrome (6).
SHORT syndrome is an autosomal dominant disorder, which 
was originally characterized as a condition of short stature, 
hyperextensibility of the joints and/or hernia, ocular depression, 
rieger anomaly, and teething delay (7–10). Subsequent evalu-
ation of additional patients revealed other prominent features, 
including partial lipodystrophy, with a selective reduction in sub-
cutaneous adipose tissue in the face, flank, and buttocks, as well 
as marked insulin resistance (7, 8). Recently, we and others have 
shown that the SHORT syndrome is associated with mutations 
in the Pik3r1 gene that encodes p85α (11–15). Most mutations 
cluster in the region encoding the C-terminal SH2 domain of 
p85α that is essential for binding of PI3K to tyrosine phospho-
rylated proteins, such as insulin receptor (IR) substrate-1 (IRS-1) 
and many growth factor receptors (11, 12, 14, 15). The most com-
mon mutation in the affected individuals is the Arg649Trp mis-
sense mutation; we have demonstrated that this mutation mark-
edly attenuates the insulin-dependent activation of the PI3K 
pathway in vitro (11). Other missense mutations (Glu489Lys, 
Arg631Gln), as well as a deletion (Ile539del), truncation (Tyr657*), 
and frame-shift insertions (Asn636Thrfs*18, Asp643Aspfs*8, 
Arg649Profs*5), have also been described (3, 7, 8, 15). In the pres-
ent study, we have generated knockin mice that are heterozygous 
for the most common mutation (Arg649Trp) observed in patients 
with SHORT syndrome to define the role of this mutation on the 
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nificant decrease in epididymal and subcutaneous adipose tissue 
in mutant animals, and an evaluation of adipocyte area revealed 
an overall decrease in adipose tissue mass, with a size distribu-
tion consistent with a higher frequency of small adipocytes in 
both depots (Supplemental Figure 2, F–I). In contrast, brown adi-
pose tissue weights, when normalized to body weight, remained 
unchanged at 9 months of age (Supplemental Figure 2J). Despite 
these alterations, liver histology as well as circulating free fatty 
acids and triglycerides remain unaltered in mutant mice (Supple-
mental Figure 4, A–C). The percentage of adipose tissue progeni-
tor cells isolated from the stromovascular fraction of epididymal 
and subcutaneous adipose tissue did not differ among the groups 
(Supplemental Figure 3A). In addition, no change in the differ-
entiation potential of preadipocytes isolated from the stromov-
ascular fraction of subcutaneous and brown adipose tissue was 
observed between the two groups (Supplemental Figure 3B).
Heterozygous mutant mice are insulin resistant. Most patients with 
SHORT syndrome are insulin resistant. Although no differences in 
fasting blood glucose levels were observed (Figure 3A and Supple-
mental Figure 5A), fed male p85αWT/R649W mice exhibited marked 
hyperglycemia when compared with controls (318.2 ± 25.3 mg/dl 
vs. 213.8 ± 15.7 mg/dl, P < 0.01; Figure 3A). Fed serum insulin lev-
els were markedly elevated in female p85αWT/R649W mice, whereas 
both fasted and fed levels were significantly elevated in male 
p85αWT/R649W mice (Figure 3B and Supplemental Figure 5B), and there 
was an increase in insulin resistance, as measured by the homeosta-
sis model assessment of insulin resistance (HOMA-IR), which was 
significantly increased in both male (1.36 ± 0.05 vs. 2.76 ± 0.29, P < 
0.001) and female (1.29 ± 0.18 vs. 1.88 ± 0.18, P < 0.05) mutant mice 
(Figure 3C and Supplemental Figure 5C). This was associated with a 
significant elevation of glucose levels during an i.p. glucose tolerance 
test in both male and female p85αWT/R649W mice compared with that 
in controls (Figure 3D and Supplemental Figure 5, D and E). Consis-
tent with insulin resistance, both male and female p85αWT/R649W mice 
showed no decrease in blood glucose during an insulin tolerance test 
compared with that in controls (Figure 3E and Supplemental Figure 
5, F and G). Euglycemic-hyperinsulinemic clamps revealed marked 
insulin resistance in male p85αWT/R649W mice, with a 58% reduction in 
the glucose infusion rate when compared with that in controls (46.4 
± 6.63 mg/kg/min vs. 73.3 ± 3.03 mg/kg/min, P < 0.01) and a con-
comitant decrease in the rate of glucose turnover when compared 
with that in controls (51.8 ± 3.44 mg/kg/min vs. 63.8 ± 2.04 mg/kg/
min, P < 0.05) (Figure 3G). In addition, hepatic glucose production 
was only suppressed by 76% in p85αWT/R649W mice compared with 
100% suppression in controls, at the concentration of insulin used (P 
< 0.01; Figure 3H). Tissue glucose uptake was evaluated by assess-
ing the uptake of 2-deoxy-[14C] glucose into skeletal muscle, brown 
fat, and epididymal white adipose tissue following the clamp period. 
Somewhat surprisingly, no difference was observed in skeletal 
muscle and brown adipose tissue glucose uptake between WT and 
mutant mice, but a very significant impairment in glucose uptake 
in white adipose tissue was observed in p85αWT/R649W mice when 
compared with that in controls (70.8 ± 12.2 nmol/g/min vs. 32.6 ± 
4.2 nmol/g/min; P < 0.01; Figure 3I and Supplemental Figure 5H). 
Oxygen consumption, carbon dioxide production, and respiratory 
exchange ratio were unaltered in p85αWT/R649W mice when compared 
with those in controls (Supplemental Figure 6, A and B).
PI3K pathway in vivo and to determine the mechanisms that con-
tribute to the complex phenotype of this disease.
Results
Heterozygosity for the Pik3r1 R649W mutation in mice leads to growth 
abnormalities. To generate a mouse model of SHORT syndrome 
that could be used to study the role of the PI3K pathway in insulin 
action and cell growth in vivo, as well as the pathophysiology of this 
disease, a synonymous mutation (Arg649Trp or R649W) was intro-
duced into the endogenous Pik3r1 locus in mice by gene targeting, 
as described in Supplemental Figure 1A (supplemental material 
available online with this article; doi:10.1172/JCI84005DS1). Suc-
cessful introduction of the mutation was confirmed by sequencing 
genomic DNA from p85αWT/WT and p85αWT/R649W animals (Supple-
mental Figure 1B). Extensive breeding of p85αWT/R649W mice failed 
to yield a single homozygous pup, suggesting that homozygosity 
for the R649W allele results in embryonic lethality. Consistent 
with clinical features of patients with SHORT syndrome, heterozy-
gous mutant animals exhibited a decrease in size compared with 
WT littermates (Figure 1A). Growth curves over the first 3 months 
of life indicated that both male and female p85αWT/R649W mice had 
significant decreases in body weight when compared with that of 
controls at all time points examined (Figure 1B). This difference 
in body weight persisted at 6 months of age, at which time male 
p85αWT/R649W mice weighed 12.8% less than controls (Figure 1C). 
Body length was also decreased at 12 weeks of age, with a mean 
nose-to-anus length of 89.4 ± 2.7 mm compared with 92.8 ± 1.8 mm 
for controls (P < 0.01; Figure 1D), and tibial length was significantly 
reduced in p85αWT/R649W mice compared with that in controls (16.3 ± 
0.08 mm vs. 16.6 ± 0.08 mm, P < 0.05; Figure 1E). These changes 
occurred despite a modest, but significant, elevation in serum IGF-1 
levels in p85αWT/R649W mice (12.3 ± 0.17 ng/dl vs. 11.4 ± 0.14 ng/dl, 
P < 0.005; Figure 1F), suggesting the presence of IGF-1 resistance 
in these animals.
Heterozygous mutant mice exhibit alterations in adipose tissue. 
Patients with SHORT syndrome exhibit partial lipodystrophy 
characterized by a selective reduction in subcutaneous adipose 
tissue (7, 8, 15). Mirroring this phenotype, p85αWT/R649W mice had 
a significant reduction in subcutaneous adipose tissue mass 
compared with that of controls (0.66 ± 0.05 g vs. 0.95 ± 0.1 g, 
P < 0.05); this occurred with no change in epididymal white or 
interscapular brown adipose tissue mass (Figure 2A). This was 
due to a significant decrease in average adipocyte size in subcu-
taneous adipose tissue (2,408 ± 29.8 μm2 vs. 3,039 ± 30.6 μm2, 
P < 0.001; Figure 2, B and C) and a change in adipocyte size dis-
tribution, with a higher frequency of smaller adipocytes (Figure 
2, D and E). No change in lean mass was observed, as assessed 
by dual-energy X-ray absorptiometry analysis. There was also 
no change in tibialis anterior or liver weight, when adjusted for 
body weight, indicating proportional growth retardation in other 
organs of p85αWT/R649W mice (Supplemental Figure 2, A–C). When 
adjusted for body weight, food and water consumption were 
unchanged in p85αWT/R649W mice, and exogenous administration 
of leptin for 72 hours led to a comparable degree of weight loss in 
control and mutant mice, suggesting that the observed decrease 
in body size is likely not due to alterations in leptin action (Sup-
plemental Figure 2, D and E). At 9 months of age, there was a sig-
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IR phosphorylation in adipose tissue, liver, and skeletal muscle 
in control animals, this response was significantly attenuated in 
p85αWT/R649W mice (Supplemental Figure 7A), despite the pres-
ence of comparable IR levels (Figure 5A). Likewise, there was a 
marked decrease in stimulated IRS-1 tyrosine 608 phosphory-
lation in adipose tissue (89%), liver (37%), and skeletal muscle 
(83%) from p85αWT/R649W mice (Figure 5A and Supplemental Fig-
ure 7B). As predicted, despite the absence of any changes in AKT 
expression, the insulin-dependent phosphorylation of AKT was 
also markedly reduced in adipose tissue (63%) and liver (73%) 
from p85αWT/R649W mice in addition to a more modest, but signifi-
cant, decrease in skeletal muscle (Figure 5, A and B). This reduc-
tion in insulin-dependent phosphorylation of AKT was associated 
with 72% and 46% reductions in AKT enzyme activity in extracts 
of liver and skeletal muscle, respectively, from mutant mice 
(Figure 5C). Immunohistochemistry revealed a robust, insulin- 
dependent increase in anti-PIP3 immunoreactivity in livers from 
p85αWT/WT mice, and this response was visibly diminished in liv-
ers from p85αWT/R649W animals (Figure 5D). Consistent with the 
decrease in AKT phosphorylation/activation, p85α WT/R649W mice 
also exhibited a decrease in insulin-stimulated phosphorylation 
of AKT substrates GSK-3α/β and FOXO1/3 in p85αWT/R649W hepa-
tocytes, despite the absence of any change in the expression of 
the IR, AKT, GSK-3β, or FOXO1 (Figure 5E and Supplemental 
Figure 8A). Insulin signaling was also assessed in differenti-
ated preadipocytes obtained from subcutaneous adipose tissue 
of control and mutant mice. In both control and mutant adipo-
cytes, insulin elicited a robust increase in IRS-1 (Y608) and IR 
phosphorylation (Supplemental Figure 7C). In contrast, whereas 
Mutant mice exhibit β cell hyperplasia and insulin secretion defect. 
Previous studies have suggested a role of the PI3K pathway in the 
regulation of the β cell secretory response (16) as well as gener-
alized effects on cell growth (4). Consistent with systemic insulin 
resistance, by 12 weeks of age, islets of p85αWT/R649W mice were 
larger than those of controls upon histological examination (Fig-
ure 4A), and quantitation of average islet area revealed a signifi-
cant 47% increase in islet area in p85αWT/R649W mice compared with 
that in controls (Figure 4B). On the other hand, secretion of insulin 
from these islets was defective. Thus, whereas control mice exhib-
ited a 2-fold increase in insulin levels 2 minutes following admin-
istration of glucose, this first-phase insulin secretion response was 
absent in p85αWT/R649W animals (Figure 4C). Furthermore, whereas 
control islets exhibited a 6.7-fold increase in insulin secretion 
when transitioned from low to high glucose, islets isolated from 
mutant animals exhibited elevated basal insulin secretion under 
low glucose conditions and failed to have an augmented insulin 
secretory response when transitioned to high glucose (Figure 4D). 
Furthermore, glucagon-like peptide 1 (GLP-1) treatment of control 
islets potentiated insulin secretion at both low and high glucose 
concentrations, while treatment of p85αWT/R649W islets with GLP-1 
failed to augment insulin secretion under low glucose conditions 
and only potentiated secretion in the presence of high glucose 
concentrations (Figure 4D).
The R649W mutation attenuates IR signaling in vivo. In order 
to characterize the molecular mechanism(s) contributing to the 
development of the insulin resistance observed in p85αWT/R649W 
mice, insulin signaling was assessed in vivo 10 minutes following 
an insulin injection. Whereas insulin elicited a robust increase in 
Figure 1. Body weight and length are decreased in p85WT/R649W mice. (A) Representative images of female p85αWT/WT (left) and p85αWT/R649W (right) mice at 24 
weeks of age. (B) Body weight of p85αWT/WT (white) and p85αWT/R649W (red) mice measured over the indicated time course. Female mice are indicated by triangular 
symbols, and male mice are indicated by circular symbols. (C) Body weight at 24 weeks of age and (D) body length, (E) tibia length, and (F) serum IGF-1 levels of 
12-week-old male animals. Results are shown as mean ± SEM (n = 9–12). *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.0005, unpaired Student’s t test.
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and Pik3r2 (and therefore devoid of p85α and p85β) with either 
WT or R649W p85α. Anti–pan p85 immunoblots confirmed the 
absence of p85α and p85β in control cells and the reconstitution of 
comparable levels of the WT or mutant p85α protein (Figure 6C). 
Reconstitution with either WT or mutant p85α had no effect on 
insulin-stimulated IR tyrosine phosphorylation when compared 
with the pBabe control (Figure 6C), but insulin-stimulated tyrosine 
608 phosphorylation of IRS-1 was reduced in R649W mutant cells 
compared with that in controls (Figure 6C). By contrast, IRS-1 
phosphorylation at tyrosine Y895 was augmented in cells which 
expressed either the WT or mutant p85α protein (Figure 6C). As 
expected, insulin-stimulated AKT phosphorylation was reduced in 
cells reconstituted with mutant p85α compared with that in con-
trols (1.2 ± 0.16-fold vs. 3.0 ± 0.16-fold, P < 0.01; Figure 6C and 
Supplemental Figure 9). All of these changes in signaling occurred 
in the absence of any change in IR, IRS-1, or AKT levels.
Structural modeling and studies in primary fibroblasts iso-
lated from patients with SHORT syndrome have suggested that 
the R649W mutation acts by reducing p85α binding to phos-
phorylated motifs on IRS-1 (7, 17, 18). To assess the interaction 
directly, we performed coimmunoprecipitation studies on p85α/ 
β-deficient embryonic fibroblasts with enforced expression of WT 
or mutant p85α. p85α could be readily detected in IRS-1 immu-
noprecipitates from WT p85α cells following insulin stimulation 
but was not detected in IRS-1 immunoprecipitates from cells 
expressing mutant p85α (Figure 6D). The same was true when we 
immunoblotted for IRS-1 in anti-p85α immunoprecipitates from 
insulin-stimulated cells (Figure 6D). Similarly, coimmunoprecip-
itation studies performed on HEK293 cells transiently transfected 
with empty plasmid or vectors encoding V5-tagged WT p85α or 
p85αR649W showed a failure of the mutant protein to bind to IRS-1 
insulin robustly increased AKT (S473/T308) phosphorylation in 
control cells, this response was attenuated in mutant adipocytes 
(Supplemental Figure 7C). Collectively, these data demonstrate 
that the mutant p85α negatively affects the ability of insulin to 
efficiently activate the PI3K pathway, as well as upstream signal-
ing, in all classical insulin target tissues. The small difference in 
AKT phosphorylation in skeletal muscle compared with that in 
other tissues in the knockin mice suggests that other regulatory 
subunits, such as p85β, may play a larger role in muscle than in 
other tissues or suggests the presence of some other compensa-
tory pathway in this tissue.
The R649W mutation impairs insulin signaling in vitro. To 
better understand the multiple effects of the p85α mutation on 
insulin signaling, immortalized brown preadipocyte cell lines 
were derived from p85αWT/WT and p85αWT/R649W mice and were 
stimulated with insulin over a 30-minute time course. Whereas 
stimulation of p85αWT/WT cells resulted in a robust, time-depen-
dent increase in IRS-1 and AKT phosphorylation, stimulation of 
p85α WT/R649W cells elicited only a modest increase in phosphory-
lation of both IRS-1 and AKT (Figure 6A). Likewise, PI3K activity 
assessed in anti–IRS-1 and anti-phosphotyrosine immunoprecip-
itates revealed a strong, insulin-dependent increase in p85αWT/WT 
cells, whereas no increase was observed in p85αWT/R649W cells (Fig-
ure 6B). This occurred with no change in the expression of p85α, 
p110α, and AKT.
In both patients and the knockin mice, the mutant p85α occurs 
in the presence of one normal p85α allele, as well as other poten-
tial regulatory subunits, such as p85β. To examine the signaling 
capacity of the mutant protein in the absence of endogenous p85α 
or p85β, we stably transfected immortalized mouse embryonic 
fibroblasts made from mice with genetic deletion of both Pik3r1 
Figure 2. p85WT/R649W mice show a selective reduction in subcutaneous adipose tissue mass. (A) Epididymal, subcutaneous, and brown adipose tissue (BAT) 
expressed as percentage of total body weight in male p85WT/WT and p85WT/R649W mice at 12 weeks of age (n = 9–10). (B) Hematoxylin and eosin staining of formalin-
fixed tissue sections of epididymal and subcutaneous white adipose tissue (original magnification, ×20). (C) Average adipocyte area and distribution of adipocyte 
size in (D) epididymal and (E) subcutaneous adipose tissue (n = 3–4). Results are shown as mean ± SEM. *P < 0.05, unpaired Student’s t test.
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dependent activation of AKT, which was reduced by >80% in 
cells expressing the mutant p85α. A modest decrease in AKT 
activation in cells expressing mutant p85α was also observed 
with EGF, although overall responsiveness to EGF was low in 
these cells (Figure 7A). Immunoblots performed with anti-actin 
antibodies confirmed equal protein loading under all conditions 
(Supplemental Figure 8B). Likewise, AKT phosphorylation in 
livers from p85αWT/R649W mice following exogenous administra-
tion of EGF was reduced compared with that in controls (Figure 
7B and Supplemental Figure 11).
When the PI3K pathway was assessed in isolated hepatocytes 
from p85αWT/WT and p85αWT/R649W mice, stimulation of AKT phos-
phorylation by insulin, IGF-1, and EGF was reduced by >50% in 
p85αWT/R649W hepatocytes compared with that in controls, with 
no change in the level of receptor activation (Figure 7C). This 
resulted in a decrease in GSK-3α/β and FOXO1/3a phosphoryla-
tion in response to all 3 ligands, with no alteration in the expres-
sion of these proteins (Figure 7C and Supplemental Figure 8C). By 
(Supplemental Figure 10). Coimmunoprecipitation studies 
were also performed to determine whether similar results were 
obtained in vivo. Although IRS-1 could be readily observed in p85α 
immunoprecipitates from the livers of WT mice following insulin 
treatment, p85α failed to precipitate IRS-1 in insulin-stimulated 
mutant livers (Figure 6E). Thus, the single R649W point mutation 
in the C-terminal SH2 domain of p85α prevented the formation of 
the p85α/IRS-1 complex both in vitro and in vivo.
The R649W mutation confers resistance to growth factors. To 
determine whether the mutation would impair activation of the 
PI3K pathway downstream of growth factors other than insulin, 
p85-deficient cells reconstituted with WT or mutant p85α were 
stimulated with insulin, PDGF, or EGF, and the extent of AKT 
phosphorylation was assessed. As noted in this and our previous 
study (11), expression of WT, but not mutant, p85α increased 
the insulin-dependent phosphorylation of AKT when compared 
with the control transfected cells (Figure 7A). Similarly, cells 
expressing WT p85α elicited a very robust increase in PDGF- 
Figure 3. p85WT/R649W mice are glucose intolerant and insulin resistant. (A) Blood glucose and (B) serum insulin levels in the fasted and fed states in 
male mice at 8 weeks of age. (C) HOMA-IR index calculated using fasting insulin and glucose values. (D) Glucose tolerance tests performed at 8 weeks 
of age in male animals. (E) Insulin tolerance tests performed in male mice at 8 weeks of age. (F) Glucose infusion rate, (G) glucose turnover, and (H) 
hepatic glucose production determined by performing euglycemic/hyperinsulinemic clamps on male mice at 16 weeks of age (n = 7–10). (I) Glucose 
uptake determined from skeletal muscle and epididymal adipose tissue obtained at the end of the clamp period (n = 7–10). Results are expressed as 
mean ± SEM (n = 9–12 per group). *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.0005, unpaired Student’s t test.
Downloaded from http://www.jci.org on January  2, 2017.   https://doi.org/10.1172/JCI84005
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
1 4 0 6 jci.org   Volume 126   Number 4   April 2016
contrast, evaluation of ERK phosphorylation revealed a normal 
response to insulin and growth factors in mutant cells, indicating 
that the R649W mutation specifically impairs activation of the 
PI3K pathway.
Discussion
Although SHORT syndrome is a rare disease, it provides a unique 
opportunity to define the role of PI3K in human metabolism and 
growth. In the current study, we have generated mice heterozy-
gous for the Pik3r1 R649W mutation, the most common muta-
tion in SHORT syndrome, to explore the role of PI3K pathways 
in insulin action, physiology, and development in vivo. Mutant 
animals recapitulate many of the features of SHORT syndrome, 
including reduced body weight and length, reduced subcutane-
ous adipose tissue mass, alterations in glucose metabolism, and 
eye abnormalities (the latter will be reported separately). More-
over, using cell lines derived from this mouse and other in vitro 
models, we demonstrate that this single amino acid mutation in 
one SH2 domain of p85α, even in a heterozygous form, can impair 
the ability of insulin and other growth factors to activate the PI3K 
pathway and exert their downstream effects. This occurs through 
a loss of p85α binding to phosphorylated motifs on IR substrates 
and, in the same manner, to the phosphorylated motifs on growth 
factor receptors. Thus, this mutation negatively affects a variety of 
processes dependent upon insulin and growth factor action.
One interesting and unexpected aspect of the pathogenesis of 
this disease is that mice carrying the mutant p85α allele, even in 
a heterozygous form, are severely insulin resistant, with markedly 
decreased insulin activation of the PI3K pathway in insulin-respon-
sive tissues, especially liver and adipose tissue. This occurs despite 
the presence of other PI3K regulatory subunits, such as p85β and 
p55γ (also known as p55PIK). This is different from the phenotype 
of mice with a loss of one p85α allele, which demonstrate improved 
insulin signaling and glucose homeostasis and are protected from 
the development of diabetes when challenged with high-fat diet 
or bred to mice with genetic insulin resistance (19–21). The cause 
of this paradoxical increase in insulin sensitivity in heterozygous 
p85α-null mice and cells is the unusual stoichiometry of p85α and 
p110α/β catalytic subunits in normal cells. p85α is in excess of 
p110α, such that p85α exists as both monomeric (not p110-bound) 
and dimeric (p110-bound) forms. In p85α heterozygous knockout 
mice, there is a decrease in monomeric p85α, with only a slight 
decrease in the amount of p85α/p110 dimer, thereby creating a sto-
ichiometric relationship that favors recruitment of the holoenzyme 
to IRS-1, leading to enhanced enzymatic activity (22). Likewise, 
overexpression of p85α in skeletal muscle increases the amount of 
monomeric p85α, leading to a reduction in insulin action and pro-
found insulin resistance (23). The fact that the heterozygous p85α 
R649W mice do not phenocopy animals with a reduction in p85α 
levels indicates that the mutant protein is not simply inactive but is 
acting in a dominant-negative fashion.
Another unexpected finding in our studies is that the R649W 
p85α mutant protein also caused defects in signaling upstream 
of PI3K. In the case of insulin action, this manifested as a signifi-
cant impairment in IR and IRS-1 tyrosine phosphorylation, which 
was observed in the knockin mouse in vivo and in some cell lines 
in vitro. While the exact mechanism of these upstream effects is 
unknown, several potential mechanisms exist, including changes 
in the activity of tyrosine phosphatases that dephosphorylate and 
inactivate the receptor and its substrates, such as protein tyrosine 
phosphatase 1B (PTP1B) and the LAR phosphatase (24, 25), or 
changes in subcellular localization or intracellular trafficking of 
Figure 4. p85WT/R649W mice exhibit islet hyperplasia and an insulin secretory defect. (A) Sections of whole pancreas stained with hematoxylin and eosin to 
visualize islets (original magnification, ×40). (B) Measurement of average islet area evaluated using ImageJ (n = 4). (C) Glucose-stimulated insulin secretion 
evaluated in 12-week-old male animals (n = 5). (D) Glucose-stimulated insulin secretion assessed in isolated islets from 10-week-old male mice in the absence 
and presence of GLP-1 (20 ng/dl) (n = 4). Results are expressed as mean ± SEM. *P < 0.05; **P < 0.01; #P < 0.0005, unpaired Student’s t test.
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these proteins mediated by changes in PI3K activity. Alternatively, 
the sustained hyperinsulinemia observed in mutant animals may 
lead to receptor desensitization and a concomitant decrease in 
insulin action, which we observed in vivo in insulin-responsive 
tissues (26–28). The decrease in the insulin-dependent phospho-
rylation of tyrosine 608 in IRS-1 that normally mediates binding of 
p85α may also reflect the fact that the mutant protein cannot bind 
to this site, leaving it more accessible to phosphotyrosine phos-
Figure 5. p85WT/R649W mice display impaired insulin signaling in vivo. (A) Analysis of insulin signaling in adipose tissue, liver, and skeletal muscle of 
p85WT/WT and p85WT/R649W mice administered insulin (5 U) or vehicle. Immunoblot analysis was performed with the indicated antibodies. (B) Quantification 
of p-AKT (S473) performed using ImageJ. Results are presented as mean ± SEM (n = 5–6 animals). (C) AKT activity was assessed in skeletal muscle and 
liver (n = 4–5 animals). (D) Immunofluorescence performed on liver sections using anti-PIP3 antibody (original magnification, ×40). (E) Immunoblot anal-
ysis of insulin signaling in primary hepatocytes isolated from p85WT/WT and p85WT/R649W mice in the absence or presence of insulin (10 nM) for the indicated 
times (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.0005, unpaired Student’s t test.
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syndrome has largely failed, most likely the result of a significant 
impairment in the IGF-1 axis.
Activation of the PI3K pathway is required for normal adipo-
genesis and insulin-dependent regulation of adipocyte metabolism 
(35–37). Although insulin is required for completion of the normal 
adipogenic program, we observed no difference in the frequency of 
adipocyte progenitor cells or the differentiation capacity of pread-
ipocytes isolated from mutant animals. It is possible that the resid-
ual activation of the PI3K pathway in mutant cells is sufficient to 
effectively promote differentiation or the action of other growth 
factors that facilitate differentiation is not perturbed to a similar 
degree. Mice with the heterozygous R649W p85α mutation exhibit 
a reduction in adipose fat mass, primarily due to a reduction in 
adipocyte size. This is similar to that in mice with a fat-specific IR 
knockout (38). Missense mutations in AKT2, which is downstream 
of PI3K, lead to severe insulin resistance and partial lipodystrophy 
in humans (39). Multiple mechanisms are likely involved in these 
phatases (7, 17). In agreement with this hypothesis, the decrease 
in phosphorylation of IRS-1 was specific to tyrosine 608, which 
is involved in p85α binding, while the phosphorylation state of 
tyrosine 895, which binds growth factor receptor–bound protein 2 
(GRB2), was not diminished in vivo or in cell models.
A variety of growth factors involved in embryonic and post-
natal development depend on PI3K for their action (29–32). Mice 
homozygous for the R649W mutation do not survive fetal life, 
and mice heterozygous for the R649W mutation exhibit a reduc-
tion in body length and tibial length, despite slightly increased 
IGF-1 levels, consistent with IGF-1 resistance. Humans with 
IGF-1 resistance due to IGF-1 receptor mutations exhibit intra-
uterine and postnatal growth defects and share some features 
with patients with SHORT syndrome, such as a growth deficit 
and craniofacial defects, including a triangular face and abnor-
mal size and positioning of the ears (33, 34). Consistent with this 
hypothesis, growth hormone therapy in patients with SHORT 
Figure 6. The p85 R649W mutant shows reduced PI3K pathway activation. (A) Insulin signaling in brown preadipocytes derived from p85αWT/WT and 
p85αWT/R649W mice. Cells were treated with insulin (10 nM) over a 30-minute time course. Insulin signaling was analyzed by immunoblotting (n = 3). (B) 
Quantification of PI3K assay measuring IRS-1-PI3K activity and PY-PI3K activity in arbitrary optical units in brown preadipocytes derived from p85αWT/WT 
and p85αWT/R649W mice. Results are presented as mean ± SEM. **P < 0.01; ***P < 0.001, unpaired Student’s t test. Cumulative data and statistical analysis 
of 3 independent experiments are presented (n = 3). (C) PI3K signaling assessed in reconstituted WT and R649W mutant immortalized mouse embryonic 
fibroblasts void of endogenous p85α/β (n = 3). pBabe was used as a control. (D) IRS-1 and p85 interaction assessed in p85α/p85β-deficient mouse embry-
onic fibroblasts reconstituted with WT or R649W mutant p85 (n = 2). (E) IRS-1 and p85 interaction assessed by coimmunoprecipitation performed in liver 
lysates from p85αWT/WT and p85αWT/R649W mice (n = 3).
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in mutant islets at low glucose but signifi-
cantly potentiated insulin secretion in high 
glucose conditions. GLP-1 stimulation has 
been demonstrated to lead to the acute stim-
ulation of IRS-2 tyrosine phosphorylation and 
the subsequent recruitment of p85α as well 
as the p85α-dependent activation of Rap (43, 
44). These data suggest that additional thera-
peutic modalities that augment insulin secre-
tion in addition to insulin therapy may be 
warranted in patients with SHORT syndrome.
In conclusion, we have generated a mouse 
model of SHORT syndrome to investigate the 
pathophysiology of this disease and study the 
role of the PI3K pathway in vivo in biological 
processes, such as intrauterine and postnatal 
growth, development, and metabolism. These 
mice recapitulate multiple aspects of the dis-
ease, including reduced growth, a selective 
reduction in subcutaneous adipose tissue and 
the development of insulin resistance, and 
type 2 diabetes. More importantly, these mice 
present a clear in vivo demonstration of the 
role of PI3K in response to insulin as well as 
several growth factors, including IGF-1, PDGF, 
and EGF. These data provide mechanistic 
insight into the physiological role of the PI3K 
pathway in development and metabolism and demonstrate that 
the myriad of traits observed in patients with SHORT syndrome 
represent a state of generalized growth factor resistance.
Methods
Antibodies. Rabbit antibodies specific for phospho-IR/IGFR (prod-
uct 3024), phospho-AKT (product 4060), pan AKT (product 4691), 
phospho-GSK-3α/β (product 8566), phospho-IRS-1 Y895 (product 
3070) p110α (product 4255), p-FOXO1/FOXO3a (product 9464), 
GSK-3β (product 9315), and FOXO1 (product 2880) were from Cell 
Signaling Technology. Phospho-IRS-1 Y608 (catalog 09-432) and 
p85 (catalog ABS233) antibodies were from EMD Millipore, and anti-
bodies for IR (sc-711), IRS-1 (sc-559), phospho-tyrosine (sc-508), and 
actin (sc-1616) were from Santa Cruz Biotechnology.
Generation of knockin mouse model with the Pik3r1 R649W muta-
tion. Construction of the targeting vector and generation of the 
p85αWT/R649W mice was performed by GenOway. Briefly, the genomic 
various lipodystrophies. Insulin is required for the stimulation of de 
novo lipogenesis and suppression of lipolysis in adipocytes. Given 
the degree of insulin resistance observed in adipose tissue from 
mutant mice, it is likely that the balance between lipid synthesis 
and lipid metabolism would favor a reduction in the steady-state 
storage of lipids, leading to an overall reduction in adipocyte size. 
Insulin is known to stimulate the phosphorylation of lamin A/C 
via an AKT-dependent mechanism, and mutations of lamin A/C, 
and this phosphorylation site in particular, are associated with lip-
odystrophies (40–42).
The deletion of p85α, but not p85β, in the β cell has been 
shown to lead to impaired first-phase insulin secretion in vivo 
(16). Similarly, we have observed an insulin secretory defect in 
mutant mice, highlighting the importance of p85α-mediated 
signaling in glucose-coupled insulin secretion. Interestingly, 
although GLP-1 was able to potentiate insulin secretion in con-
trol islets, GLP-1 stimulation failed to augment insulin secretion 
Figure 7. The R649W mutant confers resistance to 
several growth factors. (A) AKT phosphorylation 
assessed in reconstituted WT and R649W mutant 
immortalized mouse embryonic fibroblasts treated 
with insulin, PDGF, and EGF for the indicated time 
course (n = 2). pBabe was used as a control. (B) 
Analysis AKT phosphorylation in livers of p85WT/WT and 
p85WT/R649W mice after administration of EGF (1 μg/g 
body weight) or vehicle for 5 minutes (n = 4–5). (C) 
Signaling in isolated primary hepatocytes following 
stimulation with insulin, IGF-1, and EGF for 10 minutes 
(n = 3). Immunoblotting was performed with the 
indicated antibodies.
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microcentrifuge at 21,130 g for 10 minutes at 4°C. Cells extracts were 
stored at –80°C or immediately subjected to SDS-PAGE. Protein 
concentrations were determined using the BCA assay according to 
the manufacturer’s instructions (Thermo Fisher Scientific). Protein 
lysates were subjected to SDS-PAGE and transferred to PVDF mem-
brane (EMD Millipore). Immunoblotting was performed using the 
indicated antibodies. Quantification of immunoblots was performed 
using ImageJ. For immunoprecipitation studies, protein lysates were 
incubated overnight with the indicated antibodies. Immune com-
plexes were captured by incubation with Protein A/G Plus-Agarose 
(Santa Cruz Biotechnology) for 1 hour at 4°C, washed 3 times with 
lysis buffer, and resolved by SDS-PAGE.
PI3K assay. Immunoprecipitations with the indicated antibod-
ies were performed overnight in buffer A containing 25 mM Tris-HCl 
(pH 7.4), 2 mM Na3VO4, 10 mM NaF, 10 mM Na4P2O7, 1 mM EGTA, 1 
mM EDTA, and 1% Nonidet P-40 supplemented with protease and 
phosphatase inhibitor cocktails (Biotools). Immune complexes were 
captured with Protein A/G Plus-Agarose (Santa Cruz Biotechnology) 
for 1 hour at 4°C. Immunoprecipitates were washed 3 times in buffer A 
containing 500 mM NaCl and 2 times in PI3K reaction buffer (20 mM 
Tris-HCl [pH 7.4], 100 mM NaCl, 0.5 mM EGTA) and suspended in 50 
μl of PI3K reaction buffer containing 0.1 mg phosphatidylinositol/ml 
(Avanti Polar Lipids). The reactions were performed for 25 minutes at 
room temperature, and phosphorylated lipids were separated by thin-
layer chromatography (TLC) as previously described (42).
AKT assay. AKT activity was assessed essentially as previously 
described (47). Briefly, cells were lysed with buffer A supplemented 
with protease and phosphatase inhibitors, and lysates were sub-
jected to immunoprecipitation with anti-AKT antibodies (Santa 
Cruz Biotechnology). Immunoprecipitates were washed 3 times 
with buffer A and once with kinase reaction buffer (50 mM Tris-HCl 
[pH 7.5], 10 mM MgCl2, and 1 mM dithiothreitol). Immunoprecip-
itates were resuspended in kinase reaction buffer, to which 50 μM 
ATP, 5 μCi [ϒ32P] ATP, and 1 μg peptide substrate was added. Fol-
lowing a 20-minute incubation at 30°C, the reaction was stopped, 
aliquots were spotted onto P-81 phosphocellulose paper and washed 
with 0.5% phosphoric acid, and radioactivity was measured.
Isolation of primary hepatocytes. The isolation of primary hepato-
cytes from WT and p85αWT/R649W animals was achieved as previously 
described with minor modifications (48). The liver was perfused via 
the portal vein with liver perfusion media (0.02% EGTA solution buf-
fer) and digested with liver digestion media (Earl’s Balanced Salts, 2% 
penicillin and streptomycin, and 0.4 mg/ml collagenase). The liver 
was excised, and hepatocytes were released by manual disruption of 
the tissue. Hepatocytes were then layered on a 90% Percoll gradient 
and centrifuged at 180 g for 10 minutes. The viable cells were recov-
ered from the bottom of the tube. Cells were seeded onto collagen-
coated plates, and the media were changed after 4 hours. Primary 
hepatocyte experiments were performed the day after isolation.
Histological analysis. Tissues were fixed overnight with neu-
tral-buffered 10% formalin at 4°C, paraffin embedded, sectioned, and 
stained with hematoxylin and eosin. Adipocyte area was determined 
by quantifying the adipocyte area of a minimum of 750 cells from 4 
to 5 animals per study group using Adiposoft image analysis software.
Statistics. All data are presented as mean ± SEM. GraphPad Prism 
software (version 6) was used to perform the statistical analysis. 
Unpaired, 1-tailed t tests or 1-way ANOVA (Tukey’s multiple compar-
region encompassing exon 17 was amplified by PCR and cloned 
into the pCR4-TOPO vector (Invitrogen). PCR-based site-directed 
mutagenesis was performed to introduce the mutation, and the 
insert was transferred into the targeting vector (CHU1-HR) contain-
ing a neomycin selection cassette flanked by FRT sites and loxP sites 
flanking exon 17 containing the R649W mutation (Supplemental 
Figure 1A). All exons and PCR fragments used for constructing the 
targeting vector were validated by DNA sequencing. The targeting 
vector was electroporated into C57Bl/6 ES cells, and G418-resistant 
clones were harvested and screened by PCR and Southern blot anal-
ysis. The recombined ES cell clones were injected into C57BL/6J 
blastocysts and were implanted into pseudopregnant females. 
PIK3R1-R649W-neo male mice were bred with female mice that 
express Flp recombinase to remove the selectable marker. Resul-
tant animals were kept on a C57Bl/6J background and housed on 
a 12-hour-light/12-hour-dark cycle, with ad libitum access to water 
and food (mouse diet F9; PMI Nutrition International).
Assessment of glucose metabolism. Blood glucose was measured in 
whole venous blood in the random fed state or following a 16-hour fast 
using the Infinity blood glucose monitoring system (USDiagnostic). 
Insulin levels were determined using an ELISA assay (Crystal Chem). 
For glucose tolerance testing, mice were fasted overnight (16 hours) 
and injected intraperitoneally with glucose at a dose of 2 g/kg body 
weight, and blood glucose concentrations were measured at the indi-
cated time points. Insulin tolerance tests were performed by intraperi-
toneal administration of insulin (1 U/kg body weight) to mice in the 
random fed state followed by measurement of blood glucose concen-
trations at the indicated time points.
Hyperinsulinemic-euglycemic clamp and in vivo glucose uptake. The 
clamp was conducted in overnight-fasted, conscious mice by the 
National Mouse Metabolic Phenotyping Center at the University of Mas-
sachusetts Medical School (45). Briefly, whole-body glucose turnover 
was assessed using a continuous infusion of [3-3H] glucose, and a bolus 
injection of 2-deoxy-[14C] glucose was used during the clamp to measure 
insulin-stimulated glucose uptake in individual organs. Biochemical 
analysis and calculations were done as previously described (45).
Islet isolation and in vitro insulin secretion assay. Islets were isolated 
using the intraductal collagenase technique (46). Intact islets were hand 
picked under a stereomicroscope and allowed to recover overnight. 
Islets of similar sizes were then further selected, and 20 islets were 
transferred to each well of a 12-well plate to perform secretion experi-
ments. Islets were preincubated in KRBH buffer supplemented with 2% 
BSA for 1 hour prior to incubation in low (2.8 mM) or high (16.7 mM) glu-
cose in the presence or absence of GLP-1 (20 ng/ml). After incubation, 
media were collected, centrifuged, and stored at –20°C for determina-
tion of insulin levels by ELISA (Crystal Chem). Islets were collected, and 
DNA was extracted and quantified to normalize data.
Cell culture and treatment. All cells were cultured in DMEM sup-
plemented with 10% FBS, penicillin, and streptomycin (Thermo 
Fisher Scientific) at 37°C and 5% CO2. Before treatment, cells were 
serum deprived in DMEM supplemented with 0.1% BSA for 3 hours 
and treated in the absence or presence of insulin, EGF, PDGF, or IGF-1 
(Peprotech) for the indicated time points.
Protein extraction and immunoblotting. Cells and tissues were 
collected and lysed/homogenized in RIPA lysis buffer (EMD Milli-
pore) supplemented with protease and phosphatase inhibitor cock-
tails (Biotools). Nuclei and insoluble debris were pelleted using a 
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